A Self-Emulsified Adjuvant System Containing Alpha-Tocopherol Induced Higher Neutralizing Antibody Responses than a Squalene Only Emulsion Against a Recombinant Cytomegalovirus (CMV) Pentamer Antigen
Preprint
- 7 November 2022
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Research for novel vaccine adjuvants remains a critical need to improve the immune responses to a recombinant vaccine antigen. Emulsion adjuvants such as AS03 and MF59, particularly in the area of Influenza vaccines, have shown antigen dose sparing and allowed reduced immunizations. It was previously demonstrated that these emulsion adjuvants can be formulated using a simpler, low shear process of self-emulsification. The role of alpha tocopherol as an immunomodulator in emulsion adjuvants is evident from the success of AS03 in the on-going covid-19 pandemic. Although, it was a challenge to formulate alpha tocopherol with a low shear process to get closer to the AS03 composition, the self-emulsified version referred as self-emulsifying adjuvant systems (SE-AS) showed comparable immune responses to AS03 when co-administered with a Quadrivalent influenza virus (QIV) vaccine. In this paper, we first optimized the SE-AS with alpha tocopherol referred to as SE-AS44 to allow sterile filtration. We compared the in vitro cytokine profile with self-emulsifying adjuvant 160 (SEA160), a squalene-only self-emulsified adjuvant with composition similar to MF59. We compared SE-AS44 and SEA160 co-administered with a recombinant cytomegalovirus (CMV) pentamer antigen, which is a less immunogenic antigen, in vivo to compare the antibody and T-cell responses, in different adjuvanted groups, in C57BL/6 mice.Keywords
All Related Versions
- Version 1, 2022-11-07, Preprints
- Published version: Pharmaceutics, 15 (1), 238.
This publication has 25 references indexed in Scilit:
- Formulation Design, Optimization and In Vivo Evaluations of an α-Tocopherol-Containing Self-Emulsified Adjuvant System using Inactivated Influenza VaccineJournal of Controlled Release, 2019
- Towards an evidence based approach for the development of adjuvanted vaccinesCurrent Opinion in Immunology, 2017
- The Development of Self-Emulsifying Oil-in-Water Emulsion Adjuvant and an Evaluation of the Impact of Droplet Size on PerformanceJournal of Pharmaceutical Sciences, 2015
- Emulsions as Vaccine Adjuvants2014
- Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in RomaniaVaccine, 2013
- Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunityVaccine, 2011
- Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6–35 monthsVaccine, 2010
- Enhanced humoral and Type 1 cellular immune responses with Fluzone® adjuvanted with a synthetic TLR4 agonist formulated in an emulsionVaccine, 2009
- MF59 Emulsion Is an Effective Delivery System for a Synthetic TLR4 Agonist (E6020)Pharmaceutical Research, 2009
- Memory T cells and vaccinesVaccine, 2003